All In MedTech

Device Trial Radar · NCT07681024

Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

May 1, 2030

Study completion May 1, 2030

Sponsor

Lead sponsor
DexCom, Inc.Public (DXCM)
Sponsor type
Industry
First posted
Jul 2, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Global Registry study

Conditions

  • Diabetes

Interventions

  • Dexcom CGM (Continuous Glucose Monitor)Device

    Use Dexcom CGM according to approved commercial use. Evaluate HbA1c over time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EvaluationsTime frame: Up to 8 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.